Immatics Updates on Ongoing ACTengine(R) Cell Therapy Programs

  Company to host conference call on Wednesday, March 17 at 8:30 am EST

 
   --First anti-tumor activity observed in heavily pre-treated solid cancer 
patients during early phases of dose escalation 
 
   --Tumor shrinkage observed in 8 out of 10 patients including one partial 
response consistent with robust biological activity of infused T cell 
products 
 
   --Treatment-emergent adverse events were transient and manageable 

To discuss the data from the dose-escalation cohort of the IMA200 series, 
Immatics will host a conference call on Wednesday, March 17, 2021 at 
8:30 am EST / 13:30 CET. The webcast and presentation can be accessed 
directly through this 
https://www.globenewswire.com/Tracker?data=uJB65U6B2TCSluwF0fu0vmMK_nRY4S3ke56lGt545Rgvc1GasLly2GkZmNyhYAgP9EQvgsg_Pkz65Mnnf-1cpDE91vfiE_8m60N-yp0pV3AwKSBpBCkj4_3EmlvzlqJZvASOXeUGoM2djUlx1tvV_NiivU8iJVRrG5u-nQHpm68= 
link. Participants may also access the slides and the webcast on the 
Immatics website in the Investors section under "Presentations" at 
https://www.globenewswire.com/Tracker?data=GT2O7OIYvyhcMVI3WW12w9RtehHHzCLRMxDPAW-47gqBfK6605LrV17oALlfkB6gt4T8XCHzpQ3nID3L1mheKHb5PcTLe6fhFXTKDVs0W3heGwKKpNqrwK8C30RnTk47GVSB7wfc7aYGadaeKhQPCnOEGqGRAcJg21tVDCTnX1s= 
https://investors.immatics.com/events-presentations. A replay of the 
webcast will be made available shortly after the conclusion of the call 
and archived on the Company's website for at least 90 days. 
https://www.marketscreener.com/quote/stock/IMMATICS-N-V-109287208/news/Press-Release-nbsp-Immatics-Presents-Data-Update-on-Dose-Escalation-from-Ongoing-ACTengine-R-Cell-32714967/